Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
6jt0BZLhKDVYCPBs
